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Mutations of codon 12 in the Ki-ras gene are frequently found in pancreatic and colorectal cancers. It has been demonstrated that
human T-cells have the potential to recognise tumours expressing mutated ras-derived peptides. However, it remains unclear
whether T-cells from a given individual can recognise the mutant peptides, which are expressed in that individual’s tumour tissues.
Mutations of the Ki-ras oncogene were analysed by the mutant-allele-specific amplification (MASA) method in pancreatic and
colorectal tumour tissues, and T-cell responses against mutated Ki-ras-derived peptides were measured by [
3H]thymidine
incorporation and IFN-g production assays. Specific T-cell responses against Ki-ras-products were found in cancer patients, whereas
no immune response was observed in normal individuals (Po0.01). Six of the eight pancreatic cancer patients (75%) and nine of 26
colorectal cancer patients (35%) had T-cell responses to mutated Ki-ras-derived-peptides. T-cell response in a given individual cannot
recognise the same mutated ras peptide, which is expressed in that individual’s tumour tissues. However, pancreatic and colorectal
cancer patients have T-cell immunity against Ki-ras-peptides, and this provides potential target for cancer immunotherapy.
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Malignant transformation is commonly associated with the
acquisition of defined and characteristic mutations of cancer-
related genes (Marx, 1989). In many circumstances, the mutations
result in the expression of aberrant proteins that disrupt the
normal regulation of cell growth and differentiation (Fearon and
Vogelstein, 1990). Several tumour antigens have been identified
and the aberrant proteins capable of inducing tumour-specific
immune responses have been studied in terms of their specificity
and their putative functional roles in oncogenesis (van der
Bruggen et al, 1991; Kawakami and Rosenberg, 1997; Nestle et al,
1998; Rosenberg et al, 1998).
Somatic mutations of the ras genes have been shown to be
involved in the malignant processes in tumorigenesis. Ki-ras
mutations are found in approximately 90% of pancreatic
adenocarcinomas and 40% of colorectal adenocarcinomas
(Bos et al, 1987; Almoguera et al, 1988; Bos, 1989) These
mutations convert the ras protein to a constitutively active protein,
resulting in stimulation of cell proliferation. In pancreatic and
colorectal cancer patients, mutated Ki-ras products are attractive
targets for cancer immunotherapy since they are not commonly
expressed in normal tissue and since T-cells’ immune system
can detect single amino-acid substitutions (Fossum et al,
1993).
In the present study, we have tested whether T-cells specific for
mutant ras peptides from a given individual with pancreatic or
colorectal cancer can recognise the same peptide expressed in that
individual’s tumour tissues.
PATIENTS AND METHODS
Patients
In total, 14 patients with pancreatic cancer, 26 patients with
colorectal cancer, and six healthy volunteers from Wakayama
Medical University Hospital were enrolled in this study. Informed
consent for the studies was obtained from all the patients in
accordance with the guideline of the Ethics Committee on Human
Research, Wakayama Medical University.
Analysis of Ki-ras mutations in codon 12
Genomic DNA was isolated from resected tumours of pancreatic
and colorectal cancer patients in operation using a DNA extraction
kit (QIAGEN). Approximately 3mm
3 of tumour materials were
homogenised, and DNA extraction was performed according to the
manufacturer’s recommendations.
To confirm the sensitivity of the mutant-allele-specific-amplifi-
cation (MASA) method, DNA extracted from two pancreatic
cancer cell lines (PANC-1, BXPC3) and two lung cancer cell
lines (A549, LU65) was examined for mutations of Ki-ras
codon 12. It has been reported that PANC-1 has a Ki-ras 12
mutation from GGT (Gly) to GAT (Asp), BXPC3 has a wild-type
allele of Ki-ras 12, A549 has a GGT (Gly) to (Ala) and LU65 has a
GGT (Gly) to (Leu) mutation (Valenzuela and Groffen, 1986; Suwa
et al, 1994).
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We analysed Ki-ras mutations using the MASA method. This
method can recognise point mutations corresponding to the 30-end
nucleotides of forward primers that have mutant 30-end sequences
(Takeda et al, 1993).
The Ki-ras mutations in codon 12 were confirmed by direct
sequencing of the above PCR products.
Peptides
The amino-acid sequences of the wild-type and mutant Ki-ras 18-
mer peptides used are shown in Table 1. The synthesis of ras-
derived peptides was based on the sequence information provided
by Dr MA Cheever (Qin et al, 1995), and purchased from TAKARA
Corp., Japan. The purity of Ki-ras peptides are more than 93%.
Cell preparation and media
Blood samples (20–40ml) from each cancer patient and from
normal individuals were obtained with informed consent. Periph-
eral blood mononuclear cells (PBMC) were isolated by density
centrifugation over Ficoll–Paque (Pharmacia, Uppsala, Sweden).
Cells were washed twice and adjusted to 2 10
6cellsml
 1 in
RPMI-1640 (GIBCO) containing 7% heat-inactivated autoserum,
10mML -glutamine, 200U of penicillin–streptomycin ml
 1, and
25mM 2-mercaptoethanol.
Lymphocyte proliferation assay
Cell aliquots suspensions (100ml) at 2 10
5cellsml
 1 were plated
into each well of round-bottomed 96-well microtiter plates
(Corning, Corning, NY, USA). PBMC were incubated without
peptides, or with 100ml of ras peptide (100mgml
 1), or with 100ml
of phytohaemagglutinin (PHA, 5mgml
 1). The plates were
incubated in a humidified atmosphere under 5% CO2/95% air at
371C for 96h and then incubated for 8h with 1m Ci (35Mbq) of
[
3H]thymidinewell
 1. Cells were then harvested, and thymidine
incorporation was determined by liquid scintillation counting.
Each determination of proliferation was carried out in at least
five replicated wells. The stimulation index (SI) was calculated by
dividing the c.p.m. (mean) obtained from each group by the c.p.m.
(mean) from autologus PBMC incubated without peptides. A
positive proliferative response was defined as an SI greater than 2
(Qin et al, 1995).
Interferon-c (IFN-c) production assay
Aliquots (2ml) of cell suspensions at 2 10
6cellsml
 1 were plated
into each well of flat-bottomed, 48-well microtiter plates (Falcon
No.3078). PBMC were incubated without peptides (no stimula-
tion), or were stimulated with Ki-ras peptide (50mgml
 1) or PHA
(5mgml
 1).
The plates were incubated in a humidified atmosphere of 5%
CO2/95% air at 371C. Primary cultures were replenished with 1ml
of fresh human interleukin-2 (IL-2)-containing inactivated auto-
serum medium (20IUml
 1) on days 5, 10 and 15, and were
stimulated with the same Ki-ras peptide (50mgml
 1) and with
autologus PBMC (1 10
6cellsml
 1), which had been inactivated
with 50mgml
 1 of mitomycin C at 371C for 30min, as antigen-
presenting cells, on day 10. Cultures were then continued for 20
days. Aliquots (1ml) of the supernatants of these cultures were
collected on days 5 (sup. 1), 10 (sup. 2), 15 (sup. 3), and 20 (sup. 4).
The supernatants were analysed for secretion of IFN-g using an
enzyme-linked immunosorbent assay (ELISA) kit (Endogen,
Boston, MA, USA). The results were expressed in IUml
 1.A
positive response to a Ki-ras peptide was defined as production of
at least 4IUml
 1 of IFN-g, which is four times greater than the
production by control, in at least one of the four supernatants
tested at least one time.
The HLA-DR and -DQ loci of healthy volunteers, pancreatic
cancer patients and colorectal cancer patients were analysed,
and the relationships between the HLA-DR and -DQ loci
and positive responses of cancer patients to peptides were
investigated.
RESULTS
Ki-ras mutation in cancer patients
Table 2 shows the results of analysis of Ki-ras codon 12 mutations
in pancreatic and colorectal cancer tissues by the MASA method.
Ki-ras mutations were found in nine of 14 (64%) pancreatic cancer
tissues and six of 26 (23%) colorectal cancer tissues. The sort of Ki-
ras codon 12 mutation in tumours was aspartic acid (67%), valine
(22%) and cysteine (11%) with pancreatic cancer patients, and
aspartic acid (50%) and valine (50%) with colorectal cancer
patients.
Lymphocyte proliferative assay
The primary lymphocyte response to Ki-ras peptides was
determined in six patients with pancreatic cancer and 11 patients
with colorectal cancer. There was no enhancement of proliferation
in response to Ki-ras peptides in the primary responses of any of
the patients including Ki-ras mutations in their own tumours. Data
were not shown.
IFN-c production assay
IFN-g production of T-cells as a consequence of Ki-ras-derived
peptide stimulation was investigated in six healthy volunteers,
eight patients with pancreatic cancer and 26 patients with
colorectal cancer. None of the healthy volunteers had a positive
immune response against Ki-ras peptides.
T-cell responses to Ki-ras peptides can be detected in
pancreatic cancer patients
Six of the eight pancreatic cancer patients (75%) had positive
responses to wild-type or mutated Ki-ras peptides (Figure 1).
Pancreatic cancer cases 1, 10 and 9 had positive responses to
mutated Ki-ras V12 peptide. Pancreatic cancer case 11 had positive
response to wild-type Ki-ras peptide. Pancreatic cancer case 12 had
positive response to Ki-ras D12 peptide. Pancreatic cancer case 7
had a positive response to wild-type and Ki-ras D12 peptides. Ki-
ras mutations were analysed in pancreatic cancer tissues from the
patients, and results showed that cases 1 and 11 had D12
mutations, case 9 had a C12 mutation, case 7 had a V12 mutation,
and cases 10 and 12 had no mutation.
Table 1 Wild-type and mutated Ki-ras peptides (18-mers) employed in
this study
Peptide name Amino-acid sequence Point mutation
Wild-type peptide
Ras G 12 (p4-21) YKLVVVGAGGVGKSALTI (GGT)
Mutated peptides
Ras V 12 (p4-21) YKLVVVGAVGVGKSALTI (GTT)
Ras C 12 (p4-21) YKLVVVGACGVGKSALTI (TGT)
Ras D 12 (p4-21) YKLVVVGADGVGKSALTI (GAT)
T-cell immunity against Ki-ras peptides
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colorectal cancer patients
Nine of 26 colorectal cancer patients (35%) had positive responses
to wild-type or mutated Ki-ras peptides (Figure 2). Colorectal
cancer cases 7, 1 and 2 had positive responses to mutated Ki-ras
D12 peptide. Colorectal cancer cases 8 and 9 had positive
responses to wild-type Ki-ras C12 peptide. Colorectal cancer cases
4 and 12 had positive response to wild-type peptide. Colorectal
cancer case 11 had positive response to mutated Ki-ras C12 and
Table 2 Ki-ras point mutations at position 12 in pancreatic and colorectal cancer tissues
Pancreatic cancer Mutation Colorectal cancer Mutation Mutation
1 Gly-Asp 1 Gly-Asp 14 Wild type
2 Gly-Asp 2 Gly-Asp 15 Wild type
3 Gly-Asp 3 Gly-Asp 16 Wild type
4 Gly-Asp 4 Gly-Val 17 Wild type
5 Gly-Asp 5 Gly-Val 18 Wild type
6 Gly-Asp 6 Gly-Val 19 Wild type
7 Gly-Val 7 Wild type 20 Wild type
8 Gly-Val 8 Wild type 21 Wild type
9 Gly-Cys 9 Wild type 22 Wild type
10 Wild type 10 Wild type 23 Wild type
11 Wild type 11 Wild type 24 Wild type
12 Wild type 12 Wild type 25 Wild type
13 Wild type 13 Wild type 26 Wild type
14 Wild type Wild type
9/14 (64%) 6/26 (23%)
Gly=glycine; Val=valine; Asp=aspartic acid; Cys=cysteine.
Figure 1 IFN-g production in T-cell response against Ki-ras peptides in pancreatic cancer patients. IFN-g production in pancreatic cancer patients: (1) Ki-
ras mutation (D) (DR4, 9; DQ3,4); (10) Ki-ras mutation ( ) (DR4, 9; DQ3, 4); (9) Ki-ras mutation (C) (DR9, 12 DQ3); (11) Ki-ras mutation (D); (12) Ki-ras
mutation ( ) (DR9, 8; DQ1, 3) (7) Ki-ras mutation (V) (DR8; 2 DQ1). The numbers (1–4) of supernatants indicate the period of exposure of T-cells
exposed to Ki-ras peptides. Supernatants 1, 2, 3 and 4 were collected on days 5, 10, 15 and 20 after primary stimulation, respectively.
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cancer tissues from the patients, and results showed that cases 1
and 2 had D12 mutations, case 4 had a C12 mutation, and cases 7–
12 had no mutation.
Thus, specific T-cell immunity against Ki-ras products was
present in cancer patients, whereas no immune response was
observed in healthy volunteers (Po0.01). Six of the eight
pancreatic cancer patients and nine of the 26 colon cancer patients
had a response to Ki-ras peptides. However, the T-cells immunity
of a given individual could not recognise the mutant ras peptide
that was expressed in the tumour tissues of that individual
(Table 3).
Relationship between HLA-DR and -DQ loci and positive
response against Ki-ras peptides in cancer patients
HLA-DR and -DQ of healthy volunteers, pancreatic cancer
patients, and colorectal cancer patients were examined. Among
five patients who had positive responses to Ki-ras V12 peptide,
three patients had DR4, DR9, DQ3 or DQ4 locus. Among four
patients who had positive responses to Ki-ras D12 peptide, three
patients had DR8 or DQ1 locus. The two patients who had positive
responses to Ki-ras C12 peptide were found to have DQ1 or
DQ3 locus. Among four patients who had positive responses
to wild-type peptide, two patients had DQ1 or DQ3 locus
(Table 4).
DISCUSSION
Activating amino-acid substitutions impair the intrinsic GTPase
activity of the ras protein and generate constitutively activated
signal complexes with transforming activity. Point mutations in
ras genes have been found in a wide variety of human and murine
cancers, especially in human pancreatic cancers (90%) and human
colorectal cancers (45%) (Bos et al, 1987; Almoguera et al, 1988;
Bos, 1989).
A large fraction of human cancers harbour point mutations in
the ras gene at codon 12, in which the normal residue is
substituted by a Val, Asp or Cys residue. From an immunological
perspective, these determinants may represent highly specific
epitopes for T-cell (CD4+ and/or CD8+) recognition in cancer
immunotherapy (Tsang et al, 1994; Fossum et al, 1995). Evaluation
of point-mutated ras as a T-cell epitope could be determined
biologically using short synthetic peptides that precisely corre-
spond to the altered sites.
Several laboratories established approaches in both murine and
human systems to evaluate point-mutated ras p21 oncogene
products as potential tumour-specific targets and to characterise
the resulting cellular immune responses.
Studies using those system have shown that mutant ras protein
is able to serve as a tumour-specific antigen (Peace et al, 1991a;
Cheever et al, 1995). T-cells from animals immunised by ras
peptides can lyse cells transformed to express the ras products
with the same mutation in animal models (Peace et al, 1991b).
Figure 2 IFN-g production in T-cell response against Ki-ras peptides in colorectal cancer patients. IFN-g production in colorectal cancer patients: (7) Ki-ras
mutation ( ) (DR4, 6; DQ1, 4) (1) Ki-ras mutation (D) (DR1, 8; DQ1) (2) Ki-ras mutation (D); (8) Ki-ras mutation ( ) (DR8, 12; DQ3, 4) (9) Ki-ras
mutation ( ) (DR2,6; DQ1); (10) Ki-ras mutation ( ) (DR2,6; DQ1,3); (11) Ki-ras mutation ( ) (DR1, 4; DQ1, 3)~; (4) Ki-ras mutation (V) (DR8; DQ1, 3);
(12) Ki-ras mutation ( ) (DR6; 9 DQ1). The numbers (1–4) of supernatants indicate the period of exposure of T-cells exposed to Ki-ras peptides.
Supernatants 1, 2, 3 and 4 were collected on days 5, 10, 15 and 20 after primary stimulation, respectively.
T-cell immunity against Ki-ras peptides
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suggested that similar T-cell responses might be present in humans
(Peace et al, 1991a). In vitro stimulation of human T-cells from
some normal individuals or cancer patients with mutant ras
peptides results in the expansion of CD4+ and CD8+ precursors,
which may exhibit cytotoxicity against autologous or MHC-
matched, antigen-bearing target cells (Fossum et al, 1994b;
Juretic et al, 1996). In addition, humoral responses specific for
ras products have been observed in colorectal cancer patients
(Takahashi et al, 1995).
Other studies showed that the human T-cells can recognise
peptides that span the mutated segment of the ras protein and that
the ras peptide-specific T-cells can respond to ras protein
containing the same substitution (Jung and Schluesener, 1991;
Gedde-Dahl et al, 1992; Fossum et al, 1994a; Qin et al, 1995).
Previous studies have identified that ras mutation-specific memory
T-cells in only two human cancer patients with follicular thyroid
cancer and colorectal cancer (Gedde-Dahl et al, 1992; Fossum et al,
1994a,b). In both of these cases, the corresponding ras mutation
could not be detected in the available tumour biopsy samples.
However, it remains unclear whether T-cells can recognise the
same mutated peptides that are expressed in tumour tissues from
the same individual tissue. We first analysed the correlation
between the peptides that induce T-cell response against Ki-ras
peptides and the Ki-ras mutations in pancreatic and colorectal
cancer tissues.
We are not able to show that T-cells can recognise the mutated
ras peptide that is expressed in the tumour cells from the same
individuals.
To assess the immune response against Ki-ras peptides in
patients with pancreatic and colorectal cancer patients, primary
proliferative response assays and IFN-gproduction assays were
done. No effect of these peptides could be detected using the
primary proliferative response assay, because of the low immuno-
genicity of the Ki-ras products. On the other hand, it was possible
to detect a Ki-ras response by twice stimulation with Ki-ras
peptides and stimulation by IL-2 in an IFN-g production assay.
The stimulation of such a low concentration of IL-2 is intended to
suppress the secretion of IFN-g from other cell sources, including
the activation of natural killer cells. The purpose of IFN-g
production assays is to determine which peptide is significant
for the T-cell activation, and actual concentration is not calculated.
We used the 18-mer peptides that can bind to class II molecule, but
not to class I molecule. Therefore, the CD4+ cells might be related
in this study. However, the primary culture in the IFN-g
production assay contains antigen-presenting cells, so CD8+ cells
may be contributed in this assay. T-cell immunity against Ki-ras
peptides was detected at lower frequency in colorectal cancer
patients than in pancreatic cancer patients. This suggested that the
immunogenicity to ras products was recognised more strongly in
pancreatic cancer patients who had a high frequency of ras
mutations in their tumour tissue, but the T-cells did not recognise
the ‘correct’ mutation. T-cells in the patients with pancreatic
cancer may have been previously exposed to similar antigens in
vivo.
We propose two possible reasons why T-cells from a given
individual cannot recognise the same mutated ras peptide
expressed in the tumour tissues of that individual.
First, the length of the peptides bound by MHC class II
molecules are not strongly constrained. Therefore, the binding of
peptides to MHC class II molecules is more promiscuous than the
binding of peptides to MHC class I molecules. Peptides that bind to
Table 3 T-cell response against K-ras peptides
Healthy volunteers
Colorectal cancer
patients
Tumor tissue
Peptides
(which sort of
No. DR, DQ Locus Peptides (which sort of response) No. DR, DQ locus Ki-ras mut. response)
1 DR4 DQ4, 7 None (T-cell response 0/10 (0%)) 7 DR4, 6 DQ1, 4 Wild type Val
2 DR8, 10 DQ1, 9 None 1 DR1, 8 DQ1 Gly-Asp Val
3 DR4, 8 DQ1, 4 None 2 NT Gly-Asp Val
4 DR9, 8 DQ3, 1 None 8 DR8, 12 DQ3, 4 Wild type Asp
5 DR4, 9 DQ3, 4 None 9 DR2, 6 DQ1 Wild type Asp
6 DR8, 9 DQ1, 3 None 10 DR2, 6 DQ1, 3 Wild type Cys
7 DR10, 2 DQ1 None 11 DR1, 4 DQ1, 3 Wild type Gly, Cys
8 DR4, 9 DQ3, 4 None 4 DR8 DQ1, 3 Gly-Val Gly
9 DR2, 8 DQ1, 6 None 12 DR6, 9 DQ1, 3 Wild type Gly
10 DR8, 4 DQ1, 4 None 3 DR6, 8 DQ1 Gly-Asp None
Pancreatic cancer patients
Tumor tissue Peptides (which sort
7 NT Gly-Val None
No DR, DQ Locus Ki-ras mut. of response) 6 DR1, 4 DQ1, 3 Gly-val None
1 DR4, 9 DQ3, 4 Gly-Asp Val 13 NT Wild type None
10 DR4, 9 DQ3, 4 Wild type Val (T-cell 14 DR4, 8 DQ1, 4 Wild type None
9 DR9, 12 DQ3 Gly-Cys Val response 6/8 15 DR2, 4 DQ1, 2 Wild type None
11 NT
a Wild type Gly (75%)2) 16 DR1, 6 DQ1, 3 Wild type None
12 DR9, 8 DQ1, 3 Wild type Asp 17 DR8, 9 DQ1, 3 Wild type None
7 DR8, 2 DQ1 Gly-Val Asp. Gly 18 DR4, 8 DQ1, 4 Wild type None
2 DR10, 9 DQ1, 3 Gly-Asp None 20 DR4, 9 DQ3, 4 Wild type None
13 DR4, 9 DQ3, 4 Wild type None 21 DR4, 6 DQ1, 4 Wild type None (T-cell
22 DR4, 6 DQ1, 4 Wild type None response
23 DR1, 4 DQ1, 3 Wild type None 9/26 (35%)*)
24 DR2, 4 DQ1, 4 Wild type None
25 DR6, 8 DQ1, 3 Wild type None
26 NT Wild type None
aNT=not tested; Gly=glycine; Val=valine; Asp=aspartic acid; Cys=cysteine. *Po0.001, compared to normal individuals.
T-cell immunity against Ki-ras peptides
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residues lie at various distances from the end of the peptide
(Rudensky et al, 1991; Rammensee et al, 1995; Hammer et al,
1994). In patients who respond to wild-type peptide, their anchor
motif of class II molecule are considered to be similar to wild-type
peptide.
Second, we speculate that tumour cells harbouring a mutation
have been eliminated by the immune system in cancer patients. Ki-
ras mutations are thought to occur as a relatively early event in the
developmental sequence of colorectal adenocarcinoma (Vogelstein
et al, 1988), and may therefore be expressed early on by most of
the tumour cells. The cancer present at the time of biopsy may
have progressed further, and may not harbour the same mutation
because the cancer cells harbouring the earlier mutation were
eliminated by the immune system in an early event of tumour
development (Nakagawa et al, 1991).
It is suggested that T-cells responding to synthetic 18-mer Ki-ras
peptides are restricted by HLA-DR or -DQ class II molecules. Ras
p21 is an internally localised biosynthetic protein and is therefore
potentially susceptible to the endogenous pathway of antigen
processing and subsequent loading with MHC class I or II
molecules. It is possible that point-mutated ras p21 proteins may
be processed through an exogenous mechanism. In this regard,
Harmer et al reported that point-mutated ras p21 proteins can be
found in the external tumour microenvironment as well as
in the plasma of tumour-bearing mice, and if so, may be available
as exogenous antigens for endosomal processing by antigen-
presenting cells and presentation to CD4+ T-cells (Harmer et al,
1991).
CD4+ T-cells are thought to play an important and central role
in immunoregulation through the production and action of
lymphokines. Accordingly, several peptide- or protein-based
immunotherapy has great therapeutic potential for cancer patients
whose tumours harbour point mutations in codon 12 of the ras p21
proto-oncogene.
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